Download PDF
Semin Neurol 2015; 35(05): 522-526
DOI: 10.1055/s-0035-1563575
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Treatment of Nystagmus

Matthew J. Thurtell
1   Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, Iowa
2   Department of Neurology, University of Iowa, Iowa City, Iowa
3   Neurology Service and Center for Prevention and Treatment of Visual Loss, Veterans Affairs Medical Center, Iowa City, Iowa
› Author Affiliations
Further Information

Publication History

Publication Date:
06 October 2015 (online)

    Permissions and Reprints

Abstract

Acquired and congenital forms of nystagmus are commonly encountered in the course of clinical practice. Although some patients are asymptomatic, many others describe disabling oscillopsia that impairs visual function, social function, and quality of life. Such patients may present to the neurologist to request treatment. Numerous treatment approaches for nystagmus have been proposed, including medical, surgical, and optical treatments. Some of the treatments aim to reduce nystagmus slow-phase speed, whereas others aim to negate the visual consequences of the nystagmus. The approach must be tailored depending on the type of nystagmus, its characteristics, and in some cases, its cause. In this review, the treatment approach for acquired and congenital forms of nystagmus is summarized with an emphasis on treatments that have been evaluated in well-designed clinical trials. Novel approaches that have not yet been evaluated in clinical trials are also discussed.

Keywords

nystagmus - oscillopsia - oculopalatal tremor - multiple sclerosis
 

  • References

  • 1 Thurtell MJ, Leigh RJ. Nystagmus and saccadic intrusions. Handb Clin Neurol 2011; 102: 333-378
    PubMedGoogle Scholar
  • 2 Pilling RF, Thompson JR, Gottlob I. Social and visual function in nystagmus. Br J Ophthalmol 2005; 89 (10) 1278-1281
    CrossrefPubMedGoogle Scholar
  • 3 McLean RJ, Windridge KC, Gottlob I. Living with nystagmus: a qualitative study. Br J Ophthalmol 2012; 96 (7) 981-986
    CrossrefPubMedGoogle Scholar
  • 4 Thurtell MJ, Leigh RJ. Therapy for nystagmus. J Neuroophthalmol 2010; 30 (4) 361-371
    CrossrefPubMedGoogle Scholar
  • 5 Thurtell MJ, Rucker JC, Tomsak RL, Leigh RJ. Medical treatment of acquired nystagmus. Expert Rev Ophthalmol 2011; 6 (3) 307-314
    CrossrefPubMedGoogle Scholar
  • 6 Strupp M, Thurtell MJ, Shaikh AG, Brandt T, Zee DS, Leigh RJ. Pharmacotherapy of vestibular and ocular motor disorders, including nystagmus. J Neurol 2011; 258 (7) 1207-1222
    CrossrefPubMedGoogle Scholar
  • 7 Currie JN, Matsuo V. The use of clonazepam in the treatment of nystagmus-induced oscillopsia. Ophthalmology 1986; 93 (7) 924-932
    CrossrefPubMedGoogle Scholar
  • 8 Young YH, Huang TW. Role of clonazepam in the treatment of idiopathic downbeat nystagmus. Laryngoscope 2001; 111 (8) 1490-1493
    CrossrefPubMedGoogle Scholar
  • 9 Averbuch-Heller L, Tusa RJ, Fuhry L , et al. A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus. Ann Neurol 1997; 41 (6) 818-825
    CrossrefPubMedGoogle Scholar
  • 10 Strupp M, Schüler O, Krafczyk S , et al. Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study. Neurology 2003; 61 (2) 165-170
    CrossrefPubMedGoogle Scholar
  • 11 Claassen J, Spiegel R, Kalla R , et al. A randomised double-blind, cross-over trial of 4-aminopyridine for downbeat nystagmus—effects on slowphase eye velocity, postural stability, locomotion and symptoms. J Neurol Neurosurg Psychiatry 2013; 84 (12) 1392-1399
    CrossrefPubMedGoogle Scholar
  • 12 Kalla R, Spiegel R, Claassen J , et al. Comparison of 10-mg doses of 4-aminopyridine and 3,4-diaminopyridine for the treatment of downbeat nystagmus. J Neuroophthalmol 2011; 31 (4) 320-325
    CrossrefPubMedGoogle Scholar
  • 13 Claassen J, Feil K, Bardins S , et al. Dalfampridine in patients with downbeat nystagmus—an observational study. J Neurol 2013; 260 (8) 1992-1996
    CrossrefPubMedGoogle Scholar
  • 14 Feil K, Claaßen J, Bardins S , et al. Effect of chlorzoxazone in patients with downbeat nystagmus: a pilot trial. Neurology 2013; 81 (13) 1152-1158
    CrossrefPubMedGoogle Scholar
  • 15 Dieterich M, Straube A, Brandt T, Paulus W, Büttner U. The effects of baclofen and cholinergic drugs on upbeat and downbeat nystagmus. J Neurol Neurosurg Psychiatry 1991; 54 (7) 627-632
    CrossrefPubMedGoogle Scholar
  • 16 Thurtell MJ, Joshi AC, Leone AC , et al. Crossover trial of gabapentin and memantine as treatment for acquired nystagmus. Ann Neurol 2010; 67 (5) 676-680
    PubMedGoogle Scholar
  • 17 Glasauer S, Kalla R, Büttner U, Strupp M, Brandt T. 4-aminopyridine restores visual ocular motor function in upbeat nystagmus. J Neurol Neurosurg Psychiatry 2005; 76 (3) 451-453
    CrossrefPubMedGoogle Scholar
  • 18 Frisén L, Wikkelsø C. Posttraumatic seesaw nystagmus abolished by ethanol ingestion. Neurology 1986; 36 (6) 841-844
    CrossrefPubMedGoogle Scholar
  • 19 Lepore FE. Ethanol-induced resolution of pathologic nystagmus. Neurology 1987; 37 (5) 887
    CrossrefPubMedGoogle Scholar
  • 20 Cochin JP, Hannequin D, Do Marcolino C , et al. Intermittent see-saw nystagmus abolished by clonazepam. Rev Neurol (Paris) 1995; 151: 60-62
    PubMedGoogle Scholar
  • 21 Halmagyi GM, Rudge P, Gresty MA, Leigh RJ, Zee DS. Treatment of periodic alternating nystagmus. Ann Neurol 1980; 8 (6) 609-611
    CrossrefPubMedGoogle Scholar
  • 22 Furman JM, Wall III C, Pang DL. Vestibular function in periodic alternating nystagmus. Brain 1990; 113 (Pt 5) 1425-1439
    CrossrefPubMedGoogle Scholar
  • 23 Garbutt S, Thakore N, Rucker J , et al. Effects of visual fixation and convergence in periodic alternating nystagmus due to MS. Neuroophthalmology 2004; 28 (5–6) 221-229
    CrossrefPubMedGoogle Scholar
  • 24 Kumar A, Thomas S, McLean R , et al. Treatment of acquired periodic alternating nystagmus with memantine: a case report. Clin Neuropharmacol 2009; 32 (2) 109-110
    CrossrefPubMedGoogle Scholar
  • 25 Starck M, Albrecht H, Pöllmann W, Dieterich M, Straube A. Acquired pendular nystagmus in multiple sclerosis: an examiner-blind cross-over treatment study of memantine and gabapentin. J Neurol 2010; 257 (3) 322-327
    CrossrefPubMedGoogle Scholar
  • 26 Starck M, Albrecht H, Pöllmann W, Straube A, Dieterich M. Drug therapy for acquired pendular nystagmus in multiple sclerosis. J Neurol 1997; 244 (1) 9-16
    PubMedGoogle Scholar
  • 27 Villoslada P, Arrondo G, Sepulcre J, Alegre M, Artieda J. Memantine induces reversible neurologic impairment in patients with MS. Neurology 2009; 72 (19) 1630-1633
    CrossrefPubMedGoogle Scholar
  • 28 Beh SC, Tehrani AS, Kheradmand A, Zee DS. Damping of monocular pendular nystagmus with vibration in a patient with multiple sclerosis. Neurology 2014; 82 (15) 1380-1381
    CrossrefPubMedGoogle Scholar
  • 29 Barton JJ, Huaman AG, Sharpe JA. Muscarinic antagonists in the treatment of acquired pendular and downbeat nystagmus: a double-blind, randomized trial of three intravenous drugs. Ann Neurol 1994; 35 (3) 319-325
    CrossrefPubMedGoogle Scholar
  • 30 Leigh RJ, Burnstine TH, Ruff RL, Kasmer RJ. Effect of anticholinergic agents upon acquired nystagmus: a double-blind study of trihexyphenidyl and tridihexethyl chloride. Neurology 1991; 41 (11) 1737-1741
    CrossrefPubMedGoogle Scholar
  • 31 Jayaramachandran P, Proudlock FA, Odedra N, Gottlob I, McLean RJ. A randomized controlled trial comparing soft contact lens and rigid gas-permeable lens wearing in infantile nystagmus. Ophthalmology 2014; 121 (9) 1827-1836
    CrossrefPubMedGoogle Scholar
  • 32 Hertle RW, Yang D, Tai Z, Carey K, Mitchell E. A systematic approach to eye muscle surgery for infantile nystagmus syndrome: results in 100 patients. Binocul Vis Strabismus Q 2010; 25 (2) 72-93
    PubMedGoogle Scholar
  • 33 McLean R, Proudlock F, Thomas S, Degg C, Gottlob I. Congenital nystagmus: randomized, controlled, double-masked trial of memantine/gabapentin. Ann Neurol 2007; 61 (2) 130-138
    CrossrefPubMedGoogle Scholar
  • 34 Thurtell MJ, Dell'osso LF, Leigh RJ, Matta M, Jacobs JB, Tomsak RL. Effects of acetazolamide on infantile nystagmus syndrome waveforms: comparisons to contact lenses and convergence in a well-studied subject. Open Ophthalmol J 2010; 4: 42-51
    CrossrefPubMedGoogle Scholar
  • 35 Dell'osso LF, Hertle RW, Leigh RJ, Jacobs JB, King S, Yaniglos S. Effects of topical brinzolamide on infantile nystagmus syndrome waveforms: eyedrops for nystagmus. J Neuroophthalmol 2011; 31 (3) 228-233
    PubMedGoogle Scholar
  • 36 Hertle RW, Yang D, Adkinson T, Reed M. Topical brinzolamide (Azopt) versus placebo in the treatment of infantile nystagmus syndrome (INS). Br J Ophthalmol 2015; 99 (4) 471-476
    CrossrefPubMedGoogle Scholar
  • 37 Jacobs JB, Dell'Osso LF, Hertle RW, Acland GM, Bennett J. Eye movement recordings as an effectiveness indicator of gene therapy in RPE65-deficient canines: implications for the ocular motor system. Invest Ophthalmol Vis Sci 2006; 47 (7) 2865-2875
    CrossrefPubMedGoogle Scholar
  • 38 Leigh RJ, Rushton DN, Thurston SE, Hertle RW, Yaniglos SS. Effects of retinal image stabilization in acquired nystagmus due to neurologic disease. Neurology 1988; 38 (1) 122-127
    CrossrefPubMedGoogle Scholar
  • 39 Stahl JS, Lehmkuhle M, Wu K, Burke B, Saghafi D, Pesh-Imam S. Prospects for treating acquired pendular nystagmus with servo-controlled optics. Invest Ophthalmol Vis Sci 2000; 41 (5) 1084-1090
    PubMedGoogle Scholar
  • 40 Leigh RJ, Tomsak RL, Grant MP , et al. Effectiveness of botulinum toxin administered to abolish acquired nystagmus. Ann Neurol 1992; 32 (5) 633-642
    CrossrefPubMedGoogle Scholar